NRX Pharmaceuticals IncNASDAQ:NRXPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.3150
- TODAY'S CHANGE (%)0.0150 (1.1538%)
- Bid / Lots1.2800/ 1
- Ask / Lots1.3400/ 1
- Open / Previous Close1.3000 / 1.3000
- Day Range
- 52 Week Range
- Volume128,551
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXP |
|---|---|---|
| 09:32 ET | 1444 | 1.3 |
| 09:42 ET | 600 | 1.3 |
| 09:48 ET | 2850 | 1.3 |
| 09:50 ET | 400 | 1.32 |
| 09:51 ET | 400 | 1.32 |
| 09:53 ET | 5500 | 1.32 |
| 09:55 ET | 4675 | 1.3 |
| 09:57 ET | 5100 | 1.3 |
| 10:36 ET | 100 | 1.3001 |
| 10:40 ET | 100 | 1.31 |
| 10:58 ET | 47491 | 1.31 |
| 11:05 ET | 100 | 1.31 |
| 11:09 ET | 300 | 1.305 |
| 11:12 ET | 1100 | 1.305 |
| 11:14 ET | 100 | 1.305 |
| 11:18 ET | 700 | 1.3 |
| 11:20 ET | 2000 | 1.305 |
| 11:21 ET | 3000 | 1.305 |
| 11:23 ET | 400 | 1.3 |
| 11:34 ET | 1000 | 1.2901 |
| 11:39 ET | 350 | 1.2919 |
| 11:48 ET | 370 | 1.2964 |
| 11:50 ET | 1000 | 1.2999 |
| 12:10 ET | 1778 | 1.2964 |
| 12:15 ET | 2000 | 1.2995 |
| 12:50 ET | 100 | 1.29 |
| 12:53 ET | 3000 | 1.2978 |
| 01:24 ET | 1587 | 1.29 |
| 01:29 ET | 350 | 1.2905 |
| 01:31 ET | 100 | 1.29 |
| 01:45 ET | 5432 | 1.29 |
| 02:05 ET | 290 | 1.2999 |
| 02:07 ET | 100 | 1.3 |
| 02:09 ET | 500 | 1.295 |
| 02:12 ET | 500 | 1.29 |
| 02:48 ET | 1750 | 1.2918 |
| 03:01 ET | 100 | 1.3 |
| 03:08 ET | 822 | 1.299 |
| 03:10 ET | 335 | 1.2988 |
| 03:14 ET | 100 | 1.2949 |
| 03:26 ET | 1000 | 1.2993 |
| 03:32 ET | 990 | 1.2952 |
| 03:33 ET | 100 | 1.3 |
| 03:51 ET | 20755 | 1.305 |
| 03:53 ET | 1300 | 1.305 |
| 03:57 ET | 223 | 1.32 |
| 04:00 ET | 530 | 1.315 |
Nov 7, 2024
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024, from 4:06PM ET on Thursday Nov 07, 2024 by Dow Jones
4:06PM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 31, 2024
NRx Pharmaceuticals added to Emerging Growth Conference 76 on October 31 and Update to Schedule, from 7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
7:00AM ET on Thursday Oct 31, 2024 by Dow Jones
Oct 30, 2024
DJ NRX Pharmaceuticals Is Maintained at Buy by EF Hutton, from 9:01AM ET on Wednesday Oct 30, 2024 by Dow Jones
9:01AM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ HOPE Therapeutics, Inc. And NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing Of A Letter Of Intent To Acquire Its First Florida Interventional Psychiatry Clinics >NRXP, from 7:47AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:47AM ET on Wednesday Oct 30, 2024 by Dow JonesHOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics, from 7:47AM ET on Wednesday Oct 30, 2024 by Dow Jones
7:47AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NRX Pharmaceuticals Inc | 14.1M | -0.8x | --- |
Sensei Biotherapeutics Inc | 14.0M | -0.5x | --- |
Biomx Inc | 13.8M | -1.7x | --- |
PharmaCyte Biotech Inc | 13.8M | 3.6x | --- |
Evaxion Biotech A/S | 13.9M | -0.1x | --- |
Inhibitor Therapeutics Inc | 15.0M | -5.0x | --- |
Company Information
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Contact Information
- Headquarters
- 1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801
- Phone
- 484-254-6134
- Fax
- 302-575-1642
Executives
- Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
- Jonathan Javitt
- Interim Chief Financial Officer
- Richard Narido
- CMC and Technical Operations Advisor
- Riccardo Panicucci
- Independent Director
- Patrick Flynn
- Independent Director
- Sharon Glied
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-1.62 |
Book Value | $-0.14 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
